Stephen J Nicholls1, Gregory G Schwartz2, Kevin A Buhr3, Henry N Ginsberg4, Jan O Johansson5, Kamyar Kalantar-Zadeh6, Ewelina Kulikowski5, Peter P Toth7,8, Norman Wong5, Michael Sweeney5, Kausik K Ray9. 1. Monash Cardiovascular Research Centre, Monash University, 246 Clayton Road, Clayton, VIC, 3168, Australia. stephen.nicholls@monash.edu. 2. Division of Cardiology, University of Colorado School of Medicine, Aurora, CO, USA. 3. Statistical Data Analysis Center, University of Wisconsin-Madison, Madison, WI, USA. 4. Irving Institute for Clinical and Translational Research, Columbia University, New York, NY, USA. 5. Resverlogix Corporation, Calgary, AB, Canada. 6. Division of Nephrology and Hypertension, University of California Irvine, Irvine, USA. 7. CGH Medical Center Sterling, Sterling, IL, USA. 8. Cicarrone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 9. Imperial Centre for Cardiovascular Disease Prevention, Imperial College, London, UK.
Abstract
BACKGROUND:Patients with diabetes and acute coronary syndrome (ACS) are at high risk for subsequent heart failure. Apabetalone is a selective inhibitor of bromodomain and extra-terminal (BET) proteins, epigenetic regulators of gene expression. Preclinical data suggest that apabetalone exerts favorable effects on pathways related to myocardial structure and function and therefore could impact subsequent heart failure events. The effect of apabetalone on heart failure events after an ACS is not currently known. METHODS: The phase 3 BETonMACE trial was a double-blind, randomized comparison of apabetalone versus placebo on the incidence of major adverse cardiovascular events (MACE) in 2425 patients with a recent ACS and diabetes. This prespecified secondary analysis investigated the impact of apabetalone on hospitalization for congestive heart failure, not previously studied. RESULTS:Patients (age 62 years, 74.4% males, 90% high-intensity statin use, LDL-C 70.3 mg/dL, HDL-C 33.3 mg/dL and HbA1c 7.3%) were followed for an average 26 months. Apabetalone treated patients experienced the nominal finding of a lower rate of first hospitalization for heart failure (2.4% vs. 4.0%, HR 0.59 [95%CI 0.38-0.94], P = 0.03), total number of hospitalizations for heart failure (35 vs. 70, HR 0.47 [95%CI 0.27-0.83], P = 0.01) and the combination of cardiovascular death or hospitalization for heart failure (5.7% vs. 7.8%, HR 0.72 [95%CI 0.53-0.98], P = 0.04). CONCLUSION:Apabetalone treatment was associated with fewer hospitalizations for heart failure in patients with type 2 diabetes and recent ACS. Future studies are warranted to define the potential for BET inhibition with apabetalone to prevent heart failure in patients with diabetes and ACS.
RCT Entities:
BACKGROUND:Patients with diabetes and acute coronary syndrome (ACS) are at high risk for subsequent heart failure. Apabetalone is a selective inhibitor of bromodomain and extra-terminal (BET) proteins, epigenetic regulators of gene expression. Preclinical data suggest that apabetalone exerts favorable effects on pathways related to myocardial structure and function and therefore could impact subsequent heart failure events. The effect of apabetalone on heart failure events after an ACS is not currently known. METHODS: The phase 3 BETonMACE trial was a double-blind, randomized comparison of apabetalone versus placebo on the incidence of major adverse cardiovascular events (MACE) in 2425 patients with a recent ACS and diabetes. This prespecified secondary analysis investigated the impact of apabetalone on hospitalization for congestive heart failure, not previously studied. RESULTS:Patients (age 62 years, 74.4% males, 90% high-intensity statin use, LDL-C 70.3 mg/dL, HDL-C 33.3 mg/dL and HbA1c 7.3%) were followed for an average 26 months. Apabetalone treated patients experienced the nominal finding of a lower rate of first hospitalization for heart failure (2.4% vs. 4.0%, HR 0.59 [95%CI 0.38-0.94], P = 0.03), total number of hospitalizations for heart failure (35 vs. 70, HR 0.47 [95%CI 0.27-0.83], P = 0.01) and the combination of cardiovascular death or hospitalization for heart failure (5.7% vs. 7.8%, HR 0.72 [95%CI 0.53-0.98], P = 0.04). CONCLUSION:Apabetalone treatment was associated with fewer hospitalizations for heart failure in patients with type 2 diabetes and recent ACS. Future studies are warranted to define the potential for BET inhibition with apabetalone to prevent heart failure in patients with diabetes and ACS.
Authors: Dean Gilham; Sylwia Wasiak; Laura M Tsujikawa; Christopher Halliday; Karen Norek; Reena G Patel; Ewelina Kulikowski; Jan Johansson; Michael Sweeney; Norman C W Wong; Allan Gordon; Kevin McLure; Peter Young Journal: Atherosclerosis Date: 2016-01-22 Impact factor: 5.162
Authors: Dana Bailey; Ravi Jahagirdar; Allan Gordon; Anouar Hafiane; Steven Campbell; Safia Chatur; Gregory S Wagner; Henrik C Hansen; Fabrizio S Chiacchia; Jan Johansson; Larbi Krimbou; Norman C W Wong; Jacques Genest Journal: J Am Coll Cardiol Date: 2010-06-08 Impact factor: 24.094
Authors: Qiming Duan; Sarah McMahon; Priti Anand; Hirsh Shah; Sean Thomas; Hazel T Salunga; Yu Huang; Rongli Zhang; Aarathi Sahadevan; Madeleine E Lemieux; Jonathan D Brown; Deepak Srivastava; James E Bradner; Timothy A McKinsey; Saptarsi M Haldar Journal: Sci Transl Med Date: 2017-05-17 Impact factor: 17.956
Authors: Ravi Jahagirdar; Haiyan Zhang; Salman Azhar; Jennifer Tobin; Sarah Attwell; Raymond Yu; Jin Wu; Kevin G McLure; Henrik C Hansen; Gregory S Wagner; Peter R Young; Rai Ajit K Srivastava; Norman C W Wong; Jan Johansson Journal: Atherosclerosis Date: 2014-06-28 Impact factor: 5.162
Authors: Kausik K Ray; Stephen J Nicholls; Kevin A Buhr; Henry N Ginsberg; Jan O Johansson; Kamyar Kalantar-Zadeh; Ewelina Kulikowski; Peter P Toth; Norman Wong; Michael Sweeney; Gregory G Schwartz Journal: JAMA Date: 2020-04-28 Impact factor: 56.272
Authors: Laura M Tsujikawa; Li Fu; Shovon Das; Christopher Halliday; Brooke D Rakai; Stephanie C Stotz; Christopher D Sarsons; Dean Gilham; Emily Daze; Sylwia Wasiak; Deborah Studer; Kristina D Rinker; Michael Sweeney; Jan O Johansson; Norman C W Wong; Ewelina Kulikowski Journal: Clin Epigenetics Date: 2019-07-12 Impact factor: 6.551
Authors: Jeffrey Cummings; Gregory G Schwartz; Stephen J Nicholls; Aziz Khan; Chris Halliday; Peter P Toth; Michael Sweeney; Jan O Johansson; Norman C W Wong; Ewelina Kulikowski; Kamyar Kalantar-Zadeh; Kenneth Lebioda; Henry N Ginsberg; Bengt Winblad; Henrik Zetterberg; Kausik K Ray Journal: J Alzheimers Dis Date: 2021 Impact factor: 4.472
Authors: Jaqueline S da Silva; Renata G J Gonçalves; Juliana F Vasques; Bruna S Rocha; Bianca Nascimento-Carlos; Tadeu L Montagnoli; Rosália Mendez-Otero; Mauro P L de Sá; Gisele Zapata-Sudo Journal: Cells Date: 2022-01-11 Impact factor: 6.600
Authors: Alexandra V Rozhkova; Veronika G Dmitrieva; Elena V Nosova; Alexander D Dergunov; Svetlana A Limborska; Liudmila V Dergunova Journal: J Cardiovasc Dev Dis Date: 2021-12-02
Authors: Gregory G Schwartz; Stephen J Nicholls; Peter P Toth; Michael Sweeney; Christopher Halliday; Jan O Johansson; Norman C W Wong; Ewelina Kulikowski; Kamyar Kalantar-Zadeh; Henry N Ginsberg; Kausik K Ray Journal: Cardiovasc Diabetol Date: 2021-06-22 Impact factor: 9.951